Annals of Surgical Oncology

, Volume 15, Issue 1, pp 16–17 | Cite as

Ductal Carcinoma in Situ: Through a Glass, Darkly

  • Michael D. Lagios
  • Melvin J. Silverstein
Breast Oncology

Today, ductal carcinoma in situ (DCIS) remains a growing clinical problem and a therapeutic conundrum, reflected by enormous volume of often contradictory literature devoted particularly to the mammographically detected form of this disease. Over the last 25 years, certain common findings have emerged from multiple independent studies that allow us to stratify the risk of a subsequent event related to the treatment of DCIS. Critical to our understanding of local control of DCIS is the ability to establish the margin status, size, and grade of an individual patient’s lesion and the availability of a thorough pathology protocol to permit reproducible evaluation and comparison between studies. One should be able to compare these pathological predictive factors, independently of specific treatments, and have an adequate follow-up for a disease that may not exhibit any recurrence in the initial 7–10 years. Two manuscripts published in this issue of the journal illustrate some of the common...


  1. 1.
    Dawood S, Broglio K, Gonzalez-Angulo AM, et al. Development of new cancers in patients with DCIS: The M.D. Anderson experience. Ann Surg Oncol 2007. doi: 10.1245/s10434-007-9661-8.
  2. 2.
    Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001; 28:400–18PubMedCrossRefGoogle Scholar
  3. 3.
    Meijnen P, Oldenburg H, Peterse J, et al. Clinical outcome after selective treatment for patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol 2007. doi: 10.1245/s10434-007-9659-2.
  4. 4.
    Eusebi V, Feudale E, Foschini MP, Micheli A, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994; 11:223–35PubMedGoogle Scholar
  5. 5.
    Bijker N, Peterse JL, Duschateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma in situ. Analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001; 19:2263–71PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  1. 1.The Breast Cancer Consultation ServiceTiburonUSA
  2. 2.Keck School of Medicine, University of Southern CaliforniaLos AngelesUSA

Personalised recommendations